Fierce Pharma

CDMO Bora locks in 5-year, $250M production agreement with GSK

With a productive working relationship between the two companies already well established, Bora Pharmaceuticals is renewing a $250 million global manufacturing agreement with British drugmaker GSK. | ...
TMCnet

Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract

Bora Pharmaceuticals Co., Ltd. ("Bora"; TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing, and GSK (LSE/NYSE: GSK) have signed a strategic agreement to renew a five-year ...
Business Wire

Bora Pharmaceuticals Announces Multi-Year Expansion for Midwest Manufacturing Site, as Upsher-Smith Entity Split is Finalized

MAPLE GROVE, Minn.--(BUSINESS WIRE)--Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), a global leader in pharmaceutical manufacturing, has announced plans for significant ...
Contract Pharma

Bora Pharmaceuticals, GSK Renew Global Manufacturing Contract for $250M

Bora Pharmaceuticals and GSK are renewing a five-year manufacturing partnership with the signing of a new strategic agreement.
FiercePharma

Bora's expansion tear continues as CDMO takes up stake in Tanvex, gains manufacturing capabilities

Bora Pharmaceuticals extended its expansion tear by taking a 30.5% stake in fellow Taiwanese drugmaker Tanvex BioPharma, boosting the CDMO’s biomanufacturing capabilities. The deal, which is expected ...